CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
a study on Lung Cancer Non-Small Cell Lung Cancer Kidney Cancer Colorectal Cancer Breast Cancer Triple-Negative Breast Cancer Cervical Cancer Ovarian Cancer Pancreatic Cancer Endometrial Cancer Sarcoma Head and Neck Cancer Head and Neck Squamous Cell Carcinoma Squamous Cell Carcinoma Bladder Cancer Metastatic Castration-Resistant Prostate Cancer Prostate Cancer Hodgkin's Lymphoma Lymphoma Non-Hodgkin Lymphoma Renal Cell Carcinoma
Non-Small Cell Lung Cancer, Renal Cell Cancer, Colorectal Cancer, Triple Negative Breast Cancer, Cervical Cancer, Ovarian Cancer, Pancreatic Cancer, Endometrial Cancer, Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Bladder Cancer, Metastatic Castration Resistant Prostate Cancer, Non-hodgkin Lymphoma, NSCLC, RCC, TNBC, mCRPC, CRC, Lung Cancer, Kidney Cancer, Rectal Cancer, Breast Cancer, Endometrial, Pancreatic, Ovarian, SCCHN, NHL, Endometrial Neoplasms, Triple Negative Breast Neoplasms, Renal Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck, Pembrolizumab, CPI-006, CPI-006 + ciforadenant, CPI-006 + pembrolizumab, Cohort1b
Lead Scientist at UCSF
- Lawrence Fong
Lawrence Fong, M.D. is the Efim Guzik Distinguished Professor in Cancer Biology in the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco, where he leads the Cancer Immunotherapy Program. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF and co-leads the Cancer Immunity and Immunotherapy Program in the Cancer Center.
- in progress, not accepting new patients
- Start Date
- Completion Date
- Corvus Pharmaceuticals, Inc.
- Phase 1 research study
- Study Type
- Expecting 378 study participants
- Last Updated